Patents by Inventor Peter Vanderslice

Peter Vanderslice has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Process to inhibit binding of the integrin &agr;4&bgr;1 , to VCAM-1 fibronectin and cyclic peptides thereof
    Patent number: 6713604
    Abstract: The present invention is directed to an isolated and purified cyclic peptide of from 5 to about 13 residues modeled after a portion of the CS1 peptide. A peptide of this invention preferably has the amino acid residue sequence of SEQ ID NO:2-14 or 16-42. The present invention is further directed to a process of selectively inhibiting the binding of &agr;4&bgr;1 integrin to a protein such as VCAM-1, fibronectin or invasin. In accordance with that process, a cell that expresses &agr;4&bgr;1 integrin is exposed to that protein in the presence of an effective inhibiting amount of such a peptide. The present invention is still further directed to a pharmaceutical composition containing a physiologically acceptable carrier and a cyclic peptide of the invention.
    Type: Grant
    Filed: May 8, 1996
    Date of Patent: March 30, 2004
    Assignee: Texas Biotechnology Corporation
    Inventors: Timothy P. Kogan, Kaijun Ren, Peter Vanderslice, Pamela J. Beck
  • Process to inhibit binding of the integrin .alpha..sub.4 .beta..sub.1 to VCAM-1 or fibronectin and cyclic peptides therefor
    Patent number: 6087330
    Abstract: The present invention is directed to an isolated and purified cyclic peptide of from 5 to about 13 residues modeled after a portion of the CS1 peptide. A peptide of this invention preferably has the amino acid residue sequence of SEQ ID NO:2-14 or 16-42. The present invention is further directed to a process of selectively inhibiting the binding of .alpha..sub.4 .beta..sub.1 integrin to a protein such as VCAM-1, fibronectin or invasin. In accordance with that process, a cell that expresses .alpha..sub.4 .beta..sub.1 integrin is exposed to that protein in the presence of an effective inhibiting amount of such a peptide. The present invention is still further directed to a pharmaceutical composition containing a physiologically acceptable carrier and a cyclic peptide of the invention.
    Type: Grant
    Filed: April 13, 1998
    Date of Patent: July 11, 2000
    Assignee: Texas Biotechnology Corporation
    Inventors: Timothy P. Kogan, Kaijun Ren, Peter Vanderslice, Pamela J. Beck
  • Process to inhibit binding of the integrin .alpha..sub.4 62 .sub.1 to VCAM-1 or fibronectin and linear peptides therefor
    Patent number: 5510332
    Abstract: The present invention is directed to an isolated and purified peptide comprising the LDV domain of the CSI peptide sequence or single amino acid substitutent analog thereof. A preferred peptide has the amino acid residue sequences shown in SEQ ID NOs:8-14, 17-23, 25, 28, and 51. The present invention is further directed to a process of inhibiting the binding of .alpha..sub.4 .beta..sub.1 integrin to a protein such as VCAM-1 or fibronectin comprising exposing a cell that expresses .alpha..sub.4 .beta..sub.1 integrin to the protein in the presence of an effective inhibiting amount of such a peptide. The present invention is still further directed to a pharmaceutical composition comprising a peptide of SEQ ID NO:8-102.
    Type: Grant
    Filed: July 7, 1994
    Date of Patent: April 23, 1996
    Assignee: Texas Biotechnology Corporation
    Inventors: Timothy P. Kogan, Kaijun Ren, Peter Vanderslice, Pamela J. Beck